RenovoRx, Inc. (RNXT) Stock Price & Analysis
RenovoRx, Inc. (RNXT) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $1.12 (+7.69%), as of the Nov 18, 2026 trading session; market cap $54.0M.
Educational signal · not a buy or sell recommendation · How to read this
RenovoRx, Inc. · RNXT · NASDAQ
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for solid tumors. Their lead product, RenovoGem, is currently in Phase III clinical trials for locally advanced pancreatic cancer.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · RenovoRx (RNXT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — bottom-tier quality underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Sound; Valuation: Rich; Growth Durability: Fading; Momentum: Rising.
- quarterly revenue $266,000 (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z -1.57 · Piotroski F 3
Holding back: weak fundamentals, a rich price
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 28 | Weak | |
| 28 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 21 | Weak | |
| 21 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.12 | |
| Change on the day | +7.69% | |
| Market capitalisation | $54.0M | — |
| Price / earnings (trailing) | -3.34 | |
| Shares traded on the day | 841.2K |
Price & events
Other perspectives
Council score for RenovoRx (RNXT): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is RenovoRx (RNXT), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. RenovoRx, Inc. (RNXT) is listed on NASDAQ. It employs 17 people. In Q3 FY2025 it reported revenue of $266,000 and net income of -$3M. The market values it at $54.0M.
What do the latest results show for RenovoRx (RNXT)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $266,000. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $266,000 | -$3M | -$0.08 (diluted) |
| Q4 FY2025 | $238,000 | -$3M | — |
| Q1 FY2026 | $563,000 | -$4M | -$0.09 (diluted) |
| Q2 FY2026 | $909,000 | -$3M | -$0.06 (diluted) |
What are the financial strengths and risks for RenovoRx (RNXT)?
Short answer · as of
The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z -1.57 · Piotroski F 3. Trailing ratios: current ratio 5.65 · earnings yield -28.3% · free-cash-flow yield -26.5%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -1.57 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How does RenovoRx compare with its peers?
Short answer
RenovoRx's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.02 Nov 18, 2026 | $255M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.96 Nov 18, 2026 | $186M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $8.32 Nov 18, 2026 | $813M | 63 5-pillar Nov 18, 2026 | |
| $3.29 Nov 18, 2026 | $505M | 60 5-pillar Nov 18, 2026 | |
| $6.89 Nov 18, 2026 | $550M | 60 5-pillar Nov 18, 2026 | |
| RenovoRx (RNXT) — this page | $1.12 | $54.0M | 21 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RNXT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RNXT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about RenovoRx (RNXT)?
Common Questions About RNXT
These answers are editorial: 1 of these 9 answers is drawn from the RNXT research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for RNXT?
RNXT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for solid tumors.
Is RNXT a good stock to buy?
Stock Expert AI does not rate RNXT buy, sell or hold. RenovoRx, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RNXT stock price today?
The last price recorded for RenovoRx, Inc. (RNXT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for RNXT?
RenovoRx faces significant risks inherent to clinical-stage biotechnology companies. The primary risk is the potential failure of RenovoGem in Phase III clinical trials, which would significantly impact the company's value.
What are the key factors to evaluate for RNXT?
RenovoRx, Inc. (RNXT) holds a MoonshotScore in the low range. RenovoGem is currently in Phase III clinical trials for the treatment of locally advanced pancreatic cancer (LAPC). Not financial advice.
How frequently does RNXT data refresh on this page?
RNXT's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RNXT's recent stock price performance?
RenovoRx, Inc. (RNXT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug-device combination (RenovoGem). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RNXT overvalued or undervalued right now?
RenovoRx, Inc. (RNXT) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of RNXT?
Fractional-share availability for RenovoRx, Inc. (RNXT) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 10 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com